Overview A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies Status: Terminated Trial end date: 2011-10-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies. Phase: Phase 1 Details Lead Sponsor: Human Genome Sciences Inc.